These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 11364018)

  • 21. Immune strategy.
    Proj Inf Perspect; 2004 Jan; (37):21-3. PubMed ID: 15119287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic options or antiretroviral anarchy?
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1999 Jan; 5(1):10-30. PubMed ID: 11366158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of GBV-C infection in HIV-1 infected patients.
    Canducci F; Uberti Foppa C; Boeri E; Racca S; Gallotta G; Grasso MA; Calori G; Lazzarin A; Clementi M
    J Biol Regul Homeost Agents; 2003; 17(2):191-4. PubMed ID: 14518722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies.
    Aquaro S; Svicher V; Schols D; Pollicita M; Antinori A; Balzarini J; Perno CF
    J Leukoc Biol; 2006 Nov; 80(5):1103-10. PubMed ID: 16931601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [New knowledge and new challenges: 4th National Conference on Retroviruses & Opportunistic Infections].
    Agosto M; Ehara R
    Sidahora; 1997; ():18-21. PubMed ID: 11364490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clarification of how HIV-1 DNA and protein immunizations may be better used to obtain HIV-1-specific mucosal and systemic immunity.
    Hinkula J
    Expert Rev Vaccines; 2007 Apr; 6(2):203-12. PubMed ID: 17408370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Mechanism of relationship between HIV infection and autoimmunity].
    Smirnova IP; Alekseev SB; Berezov TT
    Vopr Med Khim; 1996; 42(3):211-6. PubMed ID: 9139452
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Antiviral drugs other than zidovudine and immunomodulator therapy for human immunodeficiency virus infection].
    Cerikcioğlu N
    Mikrobiyol Bul; 1989 Jul; 23(3):255-68. PubMed ID: 2487467
    [No Abstract]   [Full Text] [Related]  

  • 29. Essiac.
    Majchrowicz MA
    Notes Undergr; 1995; (no 29):6-7. PubMed ID: 11362284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypothesis: potential utility of pyridoxal 5'-phosphate (vitamin B6) and levamisole in immune modulation and HIV-1 infection.
    Salhany JM; Stevenson M
    AIDS Patient Care STDS; 1996 Dec; 10(6):353-6. PubMed ID: 11361551
    [No Abstract]   [Full Text] [Related]  

  • 31. Host-directed and immune-based therapies for human immunodeficiency virus infection.
    Lederman MM
    Ann Intern Med; 1995 Feb; 122(3):218-22. PubMed ID: 7810941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Making drugs count. A new test could customize therapies-and boost profits.
    Rennie J
    Sci Am; 1994 Oct; 271(4):132. PubMed ID: 7939561
    [No Abstract]   [Full Text] [Related]  

  • 33. Recent thoughts on the immunotherapy of infectious diseases including HIV infection.
    Hadden JW
    Adv Exp Med Biol; 1992; 319():13-22. PubMed ID: 1414588
    [No Abstract]   [Full Text] [Related]  

  • 34. The cationic amphiphilic molecules as potential immunostimulants for HIV-1 infection.
    Achour A
    Int J Antimicrob Agents; 2001 Sep; 18(3):274-5. PubMed ID: 11673042
    [No Abstract]   [Full Text] [Related]  

  • 35. Conference summary: novel HIV therapies--from discovery to clinical proof of concept.
    Miller RH; Turk SR; Black RJ; Bridges S; Sarver N
    AIDS Res Hum Retroviruses; 1996 Jul; 12(10):859-65. PubMed ID: 8798970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new chapter in HIV.
    Lancet Infect Dis; 2014 Jul; 14(7):533. PubMed ID: 24964933
    [No Abstract]   [Full Text] [Related]  

  • 37. Novel HIV strategies previewed.
    Smart T
    GMHC Treat Issues; 1996 Dec; 10(12):6-7. PubMed ID: 11364018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How far can you knock down HIV? An interview with David D. Ho, MD. Interview by Mark Mascolini.
    Ho DD
    J Int Assoc Physicians AIDS Care; 1997 Jun; 3(6):40-4. PubMed ID: 11364429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.